ChiRhoClin

Founded in 1991 by Dr. Edward D. Purich, ChiRhoClin is a specialized pharmaceutical company dedicated to orphan theranostics for gastrointestinal and pancreatic disorders. Its core achievement is the FDA approval and commercialization of ChiRhoStim® (Synthetic Human Secretin), used in diagnostic pancreatic function tests and to facilitate endoscopic retrograde cholangiopancreatography (ERCP). The company maintains a research-oriented culture, supports academic research through grant programs, and collaborates with major medical institutions on ongoing clinical studies in pancreatic cancer and pancreatitis.

Specialization in the synthetic production and clinical application of the peptide hormone secretin for diagnostic (pancreatic function testing) and therapeutic (facilitation of endoscopic procedures) uses in gastrointestinal and pancreatic diseases.

ChiRhoClin faces limited direct competition for its FDA-approved synthetic human secretin in its specific ERCP facilitation and pancreatic function test indications. Broader competition exists from alternative diagnostic modalities (imaging, other tests) and the standard of performing ERCP without pharmacological aid. Its differentiation lies in its specialized expertise, orphan drug status, and deep integration with the clinical and academic gastroenterology community.